Payment overview · 2025
General Payments
$809.87
41 reported records · 14 companies
Healthcare provider profile · identity verified
Robert W Secor, MD
Allopathic & Osteopathic Physicians|Family Medicine · SYCAMORE, OH · NPI 1861494478
Verified facts
What the public records show
CMS Open Payments records show Robert W Secor, MD received $809.87 in general payments during 2025 across 41 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Rybelsus, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $196.92 | 24.3% | 10 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $120.86 | 14.9% | 3 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $79.34 | 9.8% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $79.08 | 9.8% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.00 | 7.4% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $56.18 | 6.9% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $50.35 | 6.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $41.87 | 5.2% | 2 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $37.01 | 4.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $25.94 | 3.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.03 | 2.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.10 | 2.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.65 | 1.8% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.54 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $809.87 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $120.86 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $114.07 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $67.12 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $56.18 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $50.35 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $46.13 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $41.87 | 2 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $37.01 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $32.95 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $31.11 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $31.04 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.89 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $28.45 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $25.94 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| ANDEXXA Normalized: andexxa |
Biological | AstraZeneca Pharmaceuticals LP | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.42 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $14.65 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $14.54 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $14.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 67 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
96 | 95 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
67 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
28 | 28 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 514 | 141 |
| Lisinopril | Lisinopril | 358 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 324 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 286 | 77 |
| Simvastatin | Simvastatin | 228 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 58 |
| Losartan Potassium | Losartan Potassium | 215 | 67 |
| Omeprazole | Omeprazole | 210 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 163 | 53 |
| Famotidine | Famotidine | 157 | 36 |
| Montelukast Sodium | Montelukast Sodium | 157 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 138 | 37 |
| Allopurinol | Allopurinol | 125 | 36 |
| Metformin Hcl | Metformin Hcl | 120 | 33 |
| Metformin Hcl Er | Metformin Hcl | 114 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 104 | 32 |
| Cephalexin | Cephalexin | 102 | 85 |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 28 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 96 | 95 |
| Carvedilol | Carvedilol | 92 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 28 |
| Buspirone Hcl | Buspirone Hcl | 89 | 24 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 81 | 22 |
| Ezetimibe | Ezetimibe | 79 | 15 |
| Gabapentin | Gabapentin | 79 | 27 |
| Potassium Chloride | Potassium Chloride | 79 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 18 |
| Meloxicam | Meloxicam | 75 | 24 |
| Glimepiride | Glimepiride | 74 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 22 |
| Furosemide | Furosemide | 68 | 23 |
| Atenolol | Atenolol | 67 | 17 |
| Azithromycin | Azithromycin | 67 | 62 |
| Eliquis | Apixaban | 67 | 18 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 67 | 47 |
| Sertraline Hcl | Sertraline Hcl | 61 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 58 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 56 | 17 |
| Ramipril | Ramipril | 55 | 16 |
| Prednisone | Prednisone | 54 | 49 |
| Farxiga | Dapagliflozin Propanediol | 52 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 11 |
| Lovastatin | Lovastatin | 49 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 34 |
| Spironolactone | Spironolactone | 31 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Sucralfate | Sucralfate | 29 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 28 | 28 |
| Warfarin Sodium | Warfarin Sodium | 28 | 11 |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 15 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 25 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | 12 |
| Fenofibrate | Fenofibrate,micronized | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Rybelsus | Semaglutide | 24 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Glipizide | Glipizide | 19 | suppressed |
| Lubiprostone | Lubiprostone | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Tiadylt Er | Diltiazem Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 11 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $809.87 · 41 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, ANDEXXA, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ENFLONSIA, EVENITY, FARXIGA, GARDASIL 9, GVOKE HYPOPEN, JAKAFI, KEYTRUDA, KEYTRUDA QLEX, Kerendia, OTEZLA, Ozempic, PENBRAYA, PREVNAR 20, PROLIA, REPATHA, ROTATEQ, Rybelsus, SHINGRIX, TRUMENBA, VIBERZI, WATCHMAN Access System, Wegovy | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error